Integra LifeSciences Holdings Corporation (IART) Income Statement
IART 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsIART revenue and net income
Where IART's revenue goes
2025Each bar shows an amount and its share of revenue. IART kept −31.6% of revenue as net income.
IART profit margins
IART growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +1.5% | +1.6% | +3.6% | +6.4% |
| Gross profit | −4.2% | −4.5% | −0.1% | +4.3% |
| Operating income | +140.5% | −34.1% | −14.7% | −1.5% |
| Net income | — | — | — | — |
| EPS (diluted) | −12.9% | −12.8% | −1.9% | +3.4% |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
IART quarterly EPS vs estimates
Integra LifeSciences beat the analyst EPS estimate in 7 of the last 8 quarters. Next report: October 21, 2026 (estimate $0.56).
IART income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.64B | $1.61B | $1.54B | $1.56B | $1.54B | $1.37B | $1.52B | $1.47B | $1.19B | $992.1M |
| Cost of revenue | $790.0M | $728.5M | $656.8M | $587.4M | $597.8M | $520.8M | $564.7M | $571.5M | $435.5M | $349.1M |
| Gross profit | $845.2M | $882.1M | $884.7M | $970.3M | $944.6M | $851.0M | $952.9M | $900.9M | $752.7M | $643.0M |
| Research & development | $99.0M | $115.4M | $104.2M | $101.2M | $93.1M | $77.4M | $79.6M | $78.0M | $63.5M | $58.2M |
| Sales, general & admin | $699.7M | $717.0M | $656.6M | $616.3M | $637.4M | $594.5M | $687.6M | $690.7M | $624.1M | $455.6M |
| Total operating expenses | $776.9M | $853.6M | $773.2M | $731.4M | $747.4M | $699.7M | $859.1M | $789.9M | $707.9M | $527.6M |
| Operating income | $68.3M | $28.4M | $111.5M | $238.9M | $197.2M | $151.4M | $93.8M | $111.0M | $44.8M | $115.3M |
| Interest income | $18.5M | $20.0M | $17.2M | $11.9M | $6.7M | $9.3M | $10.8M | $2.8M | $255,000 | $24,000 |
| Interest expense | $86.3M | $70.6M | $51.4M | $49.6M | $50.4M | $71.6M | $54.0M | $64.7M | $35.0M | $25.8M |
| Income before taxes | −$563.5M | −$18.2M | $81.1M | $213.9M | $214.7M | $93.5M | $60.1M | $57.4M | $11.4M | $90.4M |
| Income taxes | −$47.0M | −$11.3M | $13.3M | $33.3M | $45.6M | −$40.4M | $9.9M | −$3.4M | −$53.4M | $15.8M |
| Net income | −$516.5M | −$6.9M | $67.7M | $180.6M | $169.1M | $133.9M | $50.2M | $60.8M | $64.7M | $74.6M |
| EBITDA | −$325.4M | $193.3M | $256.0M | $381.8M | $362.5M | $265.0M | $223.5M | $236.1M | $135.3M | $231.7M |
| EPS (diluted) | $2.23 | $2.56 | $3.10 | $3.36 | $3.18 | $2.45 | $2.74 | $2.42 | $1.93 | $1.76 |
| Gross margin | 51.7% | 54.8% | 57.4% | 62.3% | 61.2% | 62.0% | 62.8% | 61.2% | 63.3% | 64.8% |
| Operating margin | 4.2% | 1.8% | 7.2% | 15.3% | 12.8% | 11.0% | 6.2% | 7.5% | 3.8% | 11.6% |
| Net margin | −31.6% | −0.4% | 4.4% | 11.6% | 11.0% | 9.8% | 3.3% | 4.1% | 5.4% | 7.5% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $418.8M | $391.9M | $434.9M | $402.1M | $415.6M | $382.7M | $442.6M | $380.8M | $418.2M | $368.9M | $397.0M | $382.4M |
| Cost of revenue | $199.0M | $167.7M | $219.6M | $176.0M | $206.3M | $188.2M | $193.6M | $180.6M | $192.3M | $162.0M | $170.5M | $164.1M |
| Gross profit | $219.7M | $224.2M | $215.4M | $226.1M | $209.3M | $194.4M | $249.1M | $200.2M | $225.9M | $206.8M | $226.5M | $218.3M |
| Research & development | $24.3M | $23.5M | $24.8M | $22.5M | $27.0M | $24.7M | $31.2M | $27.4M | $29.8M | $27.0M | $24.3M | $26.6M |
| Sales, general & admin | $172.4M | $178.2M | $169.3M | $169.0M | $179.9M | $181.5M | $178.5M | $177.2M | $195.5M | $165.8M | $163.1M | $161.9M |
| Total operating expenses | $200.5M | $184.2M | −$340.8M | $185.8M | $722.0M | $209.9M | $213.4M | $208.4M | $228.9M | $202.9M | $190.4M | $191.8M |
| Operating income | $19.3M | $40.1M | $556.2M | $40.3M | −$512.7M | −$15.5M | $35.6M | −$8.2M | −$3.0M | $4.0M | $36.0M | $26.6M |
| Interest income | $4.3M | $4.1M | $4.4M | $5.0M | $4.7M | $4.4M | $4.9M | $5.0M | $5.1M | $5.0M | $4.5M | $4.6M |
| Interest expense | $23.0M | $26.8M | $23.7M | $22.7M | $21.0M | $20.2M | $19.0M | $19.4M | $18.7M | $13.6M | $13.8M | $13.1M |
| Income before taxes | $4.7M | −$2.4M | $4.3M | −$6.8M | −$531.0M | −$30.0M | $22.5M | −$20.4M | −$15.2M | −$5.2M | $28.9M | $18.6M |
| Income taxes | $262,000 | $2.2M | $6.0M | −$1.4M | −$46.9M | −$4.7M | $3.1M | −$9.7M | −$2.8M | −$1.9M | $9.0M | −$888,000 |
| Net income | $4.5M | −$4.6M | −$1.7M | −$5.4M | −$484.1M | −$25.3M | $19.4M | −$10.7M | −$12.4M | −$3.3M | $19.8M | $19.5M |
| EBITDA | $65.9M | $62.9M | $66.4M | $54.4M | −$472.2M | $26.0M | $79.1M | $35.0M | $40.2M | $39.0M | $73.6M | $62.2M |
| EPS (diluted) | $0.56 | $0.54 | $0.83 | $0.54 | $0.45 | $0.41 | $0.97 | $0.41 | $0.63 | $0.55 | $0.89 | $0.76 |
| Gross margin | 52.5% | 57.2% | 49.5% | 56.2% | 50.4% | 50.8% | 56.3% | 52.6% | 54.0% | 56.1% | 57.0% | 57.1% |
| Operating margin | 4.6% | 10.2% | 127.9% | 10.0% | −123.4% | −4.0% | 8.0% | −2.1% | −0.7% | 1.1% | 9.1% | 7.0% |
| Net margin | 1.1% | −1.2% | −0.4% | −1.3% | −116.5% | −6.6% | 4.4% | −2.8% | −3.0% | −0.9% | 5.0% | 5.1% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in IART's financial statements (latest annual report filed February 26, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
IART financial results
In fiscal year 2025 (ended December 31, 2025), Integra LifeSciences reported revenue of $1.6 billion, up 1.5% from the year before. It had a net loss of $516.5 million, a net profit margin of −31.6%. Diluted earnings per share came to $2.23. Over five years revenue grew at an average rate of 3.6% a year.
See the IART stock overview for the latest quote and news, or the IART chart for price history and technical indicators.
IART income statement FAQ
What is Integra LifeSciences's annual revenue?
Integra LifeSciences reported total revenue of $1.6 billion for fiscal year 2025, which ended on December 31, 2025. That was up 1.5% from $1.6 billion the previous year.
Is Integra LifeSciences profitable?
No. Integra LifeSciences reported a net loss of $516.5 million in fiscal 2025, a net profit margin of −31.6%; its operating margin was 4.2%.
What is Integra LifeSciences's gross margin?
Integra LifeSciences's gross margin was 51.7% in fiscal 2025: for every $100 of revenue, Integra LifeSciences kept $52 after the direct cost of its products and services.
How much does Integra LifeSciences spend on research and development?
Integra LifeSciences spent $99.0 million on research and development in fiscal 2025, 6.1% of revenue.
How fast is Integra LifeSciences growing?
Revenue grew 3.6% a year on average over the last five fiscal years, from $1.4 billion to $1.6 billion.
What are Integra LifeSciences's earnings per share?
Integra LifeSciences earned $2.23 per diluted share in fiscal 2025, compared with $2.56 a year earlier.
When will Integra LifeSciences report its next earnings?
Integra LifeSciences is expected to report results for the quarter ending September 30, 2026 on October 21, 2026 before the market opens.
When does Integra LifeSciences's fiscal year end?
Integra LifeSciences's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 26, 2026.